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ABSTRACT 
BACKGROUND: Metabolic syndrome is a 
cluster of risk factors that is responsible for the 
risk of coronary heart disease and stroke. 
Therefore, the aim of this study was to assess the 
prevalence of MetS and its components among 
T2DM patients.
METHODS: A cross-sectional study was 
conducted at the Diabetes Clinic of the Hospital, 
from June to July, 2015. Data were entered into 
EPI INFO software and exported to SPSS 20 for 
analysis. MetS prevalence was estimated using 
NCEP ATPIII and IDF criteria. Anthropometric 
measurements, investigations of serum glucose 
and lipid profiles were done. Logistic regression 
analysis was used to evaluate associated factors. 
A P-value ≤ 0.05 was considered statistically 
significant. 
RESULT: A total of 159 participants were 
included in the study; 119 (59.7%) were females 
with mean (±SD) age of (49.8±8.7) year. The 
prevalence of MetS was 66.7% in NCEP-ATP III 
and 53.5% in IDF definitions. The most 
prevalent component of MetS was elevated 
triglyceride (56.6% in ATPIII and 62.3% in IDF 
criteria), followed by abdominal obesity (61%) 
IDF and elevated blood pressure (55.4%) NCEP-
ATPIII criteria. The regression analysis showed 
that increased age, being female, high BMI,
having diabetes for over 5 years and poor 
glycemic control were significantly associated 
with metabolic syndrome.
CONCLUSION: The prevalence of MetS and its 
components among T2DM patients were high, 
suggesting that diabetic patients are at increased 
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risk of CVD and other complications. Efforts 
should be geared towards addressing these 
abnormalities through lifestyle modification, 
health awareness and medications in order to 
reduce this complication.
KEYWORDS: NCEP-ATPIII, IDF, Type 2 DM, 
Metabolic syndrome, Ethiopia, University of 
Gondar Hospital
INTRODUCTION 
Metabolic syndrome (MetS) is a cluster of 
interconnected dangerous heart attack risk factors 
that directly increase the risk of cardiovascular 
diseases (CVD), and type 2 diabetes mellitus 
(T2DM). It is a highly prevalent and major public 
health challenge among adults in developed 
countries and an emerging health problem in 
developing countries (1).
Many international organizations and expert 
groups, such as the World Health Organization 
(WHO), the European Group for the study of 
Insulin Resistance, the National Cholesterol 
Education Program Adult Treatment Panel III 
(NCEP:ATPIII), the American Association of 
Clinical Endocrinology, the International Diabetes 
Federation (IDF) and the American Heart 
Association/National Heart, Lung and Blood 
Institute have endeavored to integrate all the 
different parameters used to define MetS.
According to these expert groups, its main 
components are raised fasting plasma glucose, 
dyslipidemia and elevation of arterial blood 
pressure (BP), while abdominal obesity and/or 
insulin resistance (IR) have gained increasing 
attention as the core manifestations of the 
syndrome (2).  It is estimated that around 20-25% 
of the world’s adult population have MetS and 
they are 3 times as likely to have a heart attack 
compared with people without the syndrome (3). 
The clustering CVD risk factors that illustrates
MetS is now considered to be the driving force for 
a new CVD epidemic and people with T2DM who 
have MetS carry a much higher risk of CVD than 
those who have T2DM alonen(4).
Diabetes mellitus (DM) and related 
complications are associated with long-term 
damage and failure of various organ systems. It
induces changes in the microvasculature, causing 
extracellular matrix protein synthesis and capillary 
basement membrane thickening which are the 
pathognomic features of diabetic 
microangiopathy, these changes in conjunction 
with advanced glycation end products oxidative 
stress, low grade inflammation and 
neovascularization of vasa vasorum can lead to 
vascular complications (5). Rapid urbanization 
and major changes in lifestyle could be driving 
this complications (6).
Evidence supported that nearly 70-80% of the 
population with DM was diagnosed with MetS (7). 
Dyslipidemia and other characteristics of MetS are 
also common in Ethiopia. In a study of 950 DM 
patients in Ethiopia, the components of MetS were 
reported: hypertension  in 46.5%, obesity in 23.4% 
and dyslipidemia in 63.5% (8). In addition, a 
meta-analysis also reported 19.6%  prevalence of 
hypertension in Ethiopian (9).
Another study in Ethiopia reported that MetS 
prevalence among hypertensive patients was 
40.7% and 39.3% (10). The more components of 
the MetS that are evident, the higher is the CVD 
mortality rate (11). Besides, genetics, physical 
inactivity, ageing, a pro-inflammatory state and 
hormonal changes may also have a causal effect, 
but the role of these vary depending with ethnic 
group (12). A study reported higher prevalence of 
the MetS (41.1%) in primary aldosteronism that 
confirms the negative effect of aldosterone excess 
on glucose metabolism (13). Currently the 
prevalence of T2DM is rising in Ethiopia 
Therefore, the aim of the study was to determine 
the prevalence and components of the MetS 
among T2DM patients at University of Gondar 
Hospital, Northwest Ethiopia. 
METHODS AND MATERIALS
Study design, period and area: A cross-sectional 
study was conducted from June to July 2015, at 
University of Gondar Hospital, Ethiopia. Gondar 
Town is located at 738 km far from Addis Ababa, 
the capital city of Ethiopia. University of Gondar 
Hospital plays an important role in teaching, 
research and community service. The hospital 
gives service for more than 8000 diabetic patients.
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Sample size and sampling technique: The 
sample size was estimated based on single 
population proportion formula using a 95%
confidence interval (CI)  and 84.8%  prevalence of 
MetS among T2DM patients from Malaysia (14)
according to the following formula:n= (Zα/2)2 P(1-
P)2/d2 where, P = proportion of MetS, Zα/2 = 
Critical value at 95% level of confidence (Z = 
1.96) d = Margin of error (5%). Based on the 
above formula, the sample size was calculated to 
be 159. Thus, during the study period, 
approximately 800 T2DM patients were estimated 
to visit the chronic disease clinic. Since the 
population during the study period was below 
10,000, the sample size correction formula was 
applied. Then, a total of 159 T2DM patients were 
included in the study. To select participants from 
the study population, direct patient flow was 
checked for one week in the chronic diseases 
clinic. The study participants were chosen at 
regular intervals from their sequence of follow-up 
visit using systematic random sampling 
techniques. 
Study participants: One hundred fifty-nine 
T2DM patients on follow-up care at the 
Universityof Gondar Hospital were recruited. All
T2DM patients attending the Hospital’s Chronic 
Illness Clinic, during the study period, were 
eligible to participate in the study. Participants 
who were pregnant, lactating mothers, patients 
with history of other chronic diseases and patients 
on treatment for lipid lowering were excluded 
from the study.
Definition of metabolic syndrome
IDF definition: According to  IDF criteria, 
patients were classified as having MetS if they had 
abdominal obesity (waist circumference of ≥94 cm 
for men and ≥80 cm women) plus two of any of 
the following components: raised TG level (≥150 
mg/dL), reduced HDL-c (<40 mg/dL in males and 
<50 mg/dL in females), raised BP (systolic BP 
≥130 or diastolic BP ≥85 mmHg) or treatment of 
previously diagnosed hypertension(3).
Modified NCEP-ATP III definition: According 
to the NCEP-ATP III criteria, patients were 
classified as having MetS if they had three or 
more of the following four risk factors:  abdominal 
obesity (waist circumference >102 cm in males 
and >88 cm in females), TG (≥150 mg/dl),
reducedHDL-c (<40 mg/dl in males and <50 
mg/dl in females), higharterial BP (≥130/85 
mmHg) (15).
Data collection and laboratory investigations
Data on the characteristics of study 
participants: Data on socio-demographic 
characteristics were collected by trained nurses 
from University of Gondar Hospital Chronic 
Illness Clinic by using semi-structured 
questionnaire. The data collection was conducted 
in accordance with the WHO STEP wise approach  
for non-communicable disease surveillance in 
developing countriesmanual (16). The systolic and 
diastolic BP were taken by qualified personnel 
using a standard mercury type analogue 
sphygmomanometer and stethoscope. To improve 
the reliability of the measurement duplicate 
measurements were taken from the upper arm with 
the hand at the heart level after the patient had 
been sitting for 5 minutes, and the averaged values
were recorded as the final BP of the patient. 
Anthropometric measurements: Anthropometric 
data were collected according to WHO STEPS 
manual (16). Weight was measured in kilograms 
(kg) using the WHO weighing scale at a precision 
of 0.1kg. Height was measured using standiometer 
while weight was recorded after measuring the 
patient bare-footed and with light clothes using a 
weight balance. On the other hand, the height 
measurement is recorded to the nearest 0.1cm. 
Waist circumference (WC) in centimeter was 
measured at the midpoint between the lowermost 
rib and the iliac crest.
Laboratory investigations: Five milliliter fasting 
blood sample was collected in plane test tubes,
and serum was extracted. The extracted serum was 
investigated for Glucose and lipid profile levels 
using Bio systems A25 (Costa Brava, Spain) 
automated clinical chemistry analyzer following
the manufacturer’s instructions. Triglycerides, 
HDL-c, LDL-c, total cholesterol was determined 
by specific enzymatic method, and glucose was 
determined by glucose oxidase method.
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Data analysis and interpretation: Data were 
entered into EPI INFO computer software and
exported to SPSS version 20 (IBM, USA). The 
data were tested for normality. Frequency 
distributions of the study participants were 
explored. Continuous variables were expressed as 
mean ± standard deviation and categorical 
variables were expressed as percentage. Bivariate 
and multivariable binary logistic regression 
analyses were used to evaluate associated risk 
factors for the outcome variable. P-value ≤ 0.2 
was used as cutoff value to include variables for 
multivariable logistic regression model. The 
prevalence estimates for MetS were determined 
according to the two definitions separately. A P-
value ≤ 0.05was considered statistically 
significant.
Data management and quality control: The 
quality of the data was checked for coherence and 
completeness. The questionnaire was pre-tested 
for its accuracy and consistency prior to actual 
data collection. Trained nurses working in the 
chronic diseases follow-up clinic were involved in 
data collection. Furthermore, the principal 
investigator gave feedback and corrections on 
daily basis to the data collectors. The proper 
functioning of instruments, laboratory reagents 
and technical performance was checked by using 
quality control samples. Normal and pathological 
control samples were run daily in order to check 
the optimal reactivity of the reagent and 
functionality of the analyzer. Therefore, to 
maintain the quality of the result, pre-analytical, 
analytical and post-analytical pre-cautions of 
quality were considered. Finally, the sample was 
processed in the clinical chemistry laboratory 
based on the manufacturer’s manual. 
RESULTS
Socio-demographic and behavioral 
characteristics of the participants: The study 
population comprised 159T2DM patients; of 
these, 95(59.7%) were females. The mean (±SD) 
age of the study participants was (49.8±8.7) years. 
The majority, 146(91.6%), of the study 
participants were urban residents, and 18(21.3%)
were smokers at the time of data collection (Table
1).
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Table 1: Socio-demographic and behavioral characteristics according to sex of T2DM patients at the 
University of Gondar Hospital, Northwest Ethiopia (n=159)
Variables Male (N %) Female (N %)   Total N (%) P-value
Age 0.039
           25-35 5(25.0) 15(75.0) 20(12.6)
           36-46 20(60.6) 13(39.4) 33(20.8)
           47-57 22(34.9) 41(65.1) 63(39.6)
            ≥58 17(39.5) 26(60.5) 43(27.0)
Residence 0.891
           Urban 59(40.4) 87(59.6) 146(91.8)
           Rural 5(39.0) 8(61.0) 13(8.2)
Religion 0.452
        Orthodox 58(40.6) 85(59.4) 143(89.9)
        Muslim 3(27.3) 8(72.7) 11(6.9)
        Protestant 3(60.0) 2(40.0) 5(3.2)
Educational status 0.000
         Illiterate 7(16.3) 36(83.7) 43(27.0)
         Primary school 19(47.5) 21(52.5) 40(25.2)
        Secondary school 9(31.0) 20(69.0) 29(18.2)
        College/University 29(61.7) 18(38.3) 47(29.6)
Marital status 0.000
         Single 2(25.0) 6(75.0) 8(5.0)
         Married 61(58.3) 60(49.6) 121(76.1)
        Widowed 1(4.8) 20(95.2) 21(13.2)
        Divorced 0(0) 9(100) 9(5.7)
Occupation 
     House wife 0(0) 61(100) 61(38.4) 0.000
     Government worker 28(58.3) 20(41.7) 48(30.2)
Non-govtal organization 13(86.7) 2(13.3) 15(9.4)
     Merchant 13(59.1) 9(40.9) 22(13.8)
      Farmer 10(76.9) 3(23.1) 13(8.2)
Monthly income 0.050
<1000 14(29.8) 33(70.2) 47(29.6)
         1000-2000 8(27.6) 21(72.4) 29(18.2)
         2001-3000 14(51..9) 13(48.1) 27(17.0)
>3001 28(50.0) 28(50.0) 56(35.2)
Physical activity 0.045
         Yes 31(50.0) 31(50.0) 62(39.0)
         No 33(34.0) 64(66.0) 97(61.0)
Alcohol in the last 1 month     0.000
      Yes 31(66.0) 16(34.0) 47(29.6)
      No 33(29.5) 79(69.5) 112(70.4)
Current smoker 0.011
      Yes 13(72.2) 5(27.8) 18(21.3)
       No 51(36.2) 90(63.8) 141(88.7)
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Sleeping duration/24hr 0.48
       6-8 hour 33(38.4) 53(61.6) 86(54.1)
       Less than 6 hour 11(52.4) 10(47.6) 21(13.2)
       Greater than 8 hour 20(38.5) 32(61.5) 52(32.7)
Over all total 64(40.3%) 95(59.7%) 159(100%)
Lipid profiles, anthropometric and clinical 
characteristics of T2DM patients: Among the 
total study participants, abnormal concentrations 
of total cholesterol (64.2%), LDL-c (57.9%), low 
HDL-c (31.5%) and high TG (62.3%) were 
observed in females compared to their male 
counterparts (Table 2).
The prevalence of MetS and individual 
components of MetS based on NCEP-ATP III 
and IDF criteria: The overall prevalences of 
MetS based on NCEP-ATPIII and IDF criteria 
were 66.7% (95%CI: 59.7-74.2) and 53.5% (95% 
CI: 45.3-61.0), respectively.  The frequencies of 
MetS components were the highest for elevated 
TG (56.6%) and elevated blood pressure (55.4%) 
using NCEP-ATPIII, and central obesity (61.0%) 
and elevated TG (62.3%) in IDF criteria. The 
prevalence and all its individual components of 
MetS were higher among female in both criteria
(Table 3).
Table 2: Lipid profiles, anthropometric and clinical characteristics according to sex of T2DM patients at 
University of Gondar Hospital, northwest Ethiopia (n=159)
Variables Male N (%) Female N (%) Total N (%) P-value
Total cholesterol (mg/dl) 0.313
<200 33(42.9) 44(57.1) 77(35.8)
   ≥200 31(37.8) 51(62.2) 82(64.2)
LDL cholesterol (mg/dl) 0.203
<130 30(44.8) 37(55.2) 67(42.1)
     ≥130 34(37.0) 58(63.0) 92(57.9)
HDL Cholesterol (mg/dl) <0.05
<40 (men), <50 (women) 22(44.0) 28(56.0) 50(31.5)
  ≥40 (men), ≥50 (women) 42(38.5) 67(61.5) 109(68.5)
Triglyceride (mg/dl) 0.60
<150 19(31.7) 41(68.3) 60(37.7)
   ≥150 45(45.5) 54(54.5) 99(62.3)
BMI    0.901
     Under weight 1(33.3) 2(66.7) 3(1.9)
    Normal weight 29(42.7) 39(57.3) 68(42.8)
    Over weight 28(40.0) 42(60.0) 70(44.0)
Obesity 6(33.3) 12(66.7) 18(11.3)
SBP(mmHg) 0.460
<130 31(41.3) 44(58.7) 75(47.2)
   ≥130 33(39.3) 51(60.7) 84(52.8)
DBP(mmHg) 0.558
<85 51(40.2) 76(59.8) 127(79.9)
   ≥85 13(40.6) 19(59.4) 32(20.1)
Waist circumference (cm) >0.05
<94(men), ≤80(women) 40(30.3) 26(69.7) 66(41.5)
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       ≥94(men), >80(women) 24(25.2) 69(74.2) 93(58.5)
Duration of DM (in year) 0.027
<5 37(49.3) 38(50.7) 75(47.2)
≥5 27(32.1) 57(67.9) 84(52.8)
Glycemic control / FBS(mg/dl) 0.546
Good (≤130) 28(43.1) 37(56.9) 65(40.9)
Poor(>130) 36(38.3) 58(61.7) 94(59.1)
Note: DBP: Diastolic Blood Pressure, SBP: Systolic Blood Pressure, BMI: Body Mass Index, LDL: Low 
density Lipoprotein, HDL: High Density Lipoprotein, mmHg: Millimeter Mercury
Table 3: The prevalence of MetS and its components according to NCEP-ATPIII and IDF criteria among 
T2DM patients at University of Gondar Hospital, northwest Ethiopia (n=159)
Variables
Diagnostic definitions of Metabolic Syndrome














Central obesity 10(14.5) 59(85.5) 69(43.4) 0.000 24(24.7) 73(75.3) 97(61.0) 0.000
Increased 
Triglyceride
45(45.5) 54(54.5) 99(56.6) 0.000 45(45.5) 54(54.5) 99(62.3) 0.000
Low HDL 
cholesterol
22(42.3) 30(57.7) 52(32.7) 0.001 22(42.3) 30(57.7) 52(32.7) 0.001
Elevated blood 
pressure




36(34.0) 70(66.0) 106(66.7) 0.020 23(35.9) 62(65.3) 85(53.5) 0.000
Note: NCEP-ATPIII: National Cholesterol Education program Adult Treatment Panel III 
           IDF: International Diabetes Federation
Clustering of components of MetSbased on 
NCEP-ATPIII and IDF criteria among 
T2DM patients: According to the NCEP-ATP 
III criteria, 57.5% males and 42.5% females had 
one additional MetS component. On the other 
hand, 36.7% males and 63.3% females had 2 
additional components of MetS (Table 4).
Factors associated with prevalence of MetS 
among T2DM patients attending at 
University of Gondar Hospital: The NCEP-
ATP III criteria on the multivariable logistic 
regression analysis indicated that age 47-57 
years (AOR= 9.22; 2.36, 36.02), age ≥58 years 
(AOR=9.90; 95%CI: 2.19, 44.72) and having 
FBS > 130mg/dl (AOR=2.88; 955CI: 1.16, 7.16) 
were found to have significant associations with 
MetS. Similarly, applying the IDF criteria for 
MetS, the multivariable regression analysis 
showed that being female (AOR =3.98; 95%CI: 
1.66, 9.54), age between 47-57 years (AOR= 
7.9; 1.63, 38.41), age ≥58 years (AOR=20.9; 
95%CI: 3.79, 114.8), having abnormal BMI 
(AOR=5.12; 95%CI: 2.02, 12.93), duration  of 
≥5 years since diagnosis of T2DM(AOR=  3.14; 
95%CI: 1.24, 7.97) and being FBS >130mg/dl 
(AOR=2.53; 95%CI: 1.01, 6.32) were found to 
have significant associations with MetS (Table 
5).
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Table 4: Clustering of components of MetSaccording to NCEP-ATPIII and IDF criteria among T2DM 
patients at University of Gondar Hospital, northwest Ethiopia (n=159)
No of component(s)
Diagnostic Definitions of Metabolic Syndrome













0 5(38.5) 8(61.5) 13(8.2) 4(57.1) 3(42.9) 7(4.4)
At least 1 23(57.5) 17(42.5) 40(25.2) 19(52.8) 17(47.2) 36(22.6)
At least 2 22(36.7) 38(63.3) 60(37.7) 21(34.4) 40(65.6) 61(38.4)
At least 3 11(30.6) 25(69.4) 36(22.6) 15(35.7) 27(64.3) 42(26.4)
At least 4 3(30.0) 7(70.0) 10(6.3) 5(38.5) 8(61.5) 13(8.2)
Note: NCEP-ATPIII:National Cholesterol Education program Adult Treatment Panel III
           IDF: International Diabetes Federation
Table 5: Bivariable and multivariable logistic regression analysis of factors associated with MetS 
among T2DM patients at University of Gondar Hospital, northwest Ethiopia (n=159).
Variables










Sex   Male 36(56.3) 28(43.8) 1.00 1.00 23(35.9) 41(64.1) 1.00
       Female 70(73.7) 25(26.3) 2.18(1.11-4.27)* 2.0(0.79-5.08) 62(65.3) 33(34.7) 3.35(1.73, 6.50)*
Age   25-35 7(35) 13(65) 1.00 1.00 4(20.0) 16(80.0) 1.00
         36-46 9(27.3) 24(72.7) 0.69(0.21-2.30) 1.39(0.33-5.86) 7(21.2) 26(78.8) 1.08(0.27-4.27)
          47-57 53(84.1) 10(15.9) 9.84(3.15-30.79)* 9.22(2.36-36.02)* 40(63.5) 23(36.5) 6.96(2.08-23.32)*
            ≥58 37(86.1) 6(13.9) 11.45(3.25-40.39)* 9.90(2.19-44.72)* 34(79.1) 9(20.9) 15.1(4.04-56.52)*
BMI(Kg/m2)
≤ 25 47(62.5) 25(37.5) 1.00 1.00 27(37.5) 45(62.5) 1.00
>25 59(67.8) 28(32.2) 1.12(0.58-2.17) 0.76(0.30-1.95) 58(66.7) 29(33.3) 3.33(1.74-6.40)*
Duration of DM 
      <5 years 36(48.0) 39(52.0) 1.00 1.00 25(33.3) 50(66.7) 1.00
      ≥5 years 70(83.3) 14(16.7) 5.42(2.61-11.25)* 2.63(1.00-6.93) 60(71.4) 24(28.6) 5.0(2.548-9.813)*
FBS(mg/dl)
≤130 29(44.6) 36(55.4) 1.00 1.00 23(35.4) 42(64.6) 1.00
>130 77(81.9) 17(18.1) 5.62(2.74-11.52)* 2.88(1.16-7.16)* 62(66.0) 32(34.0) 3.54(1.82-6.87)*
Physical activity
         Yes 33(45.8) 39(54.2) 1.00 1.00 27(37.5) 45(62.5) 1.00
          No 73(83.9) 14(16.1) 6.16(2.95-12.87)* 0.42(0.17-1.07) 58(66.7) 29(33.3) 3.33(1.74-6.40)*
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Alcohol in the 
last 1 month     
      Yes 70(73.7) 25(26.3) 2.18(1.11-4.27)* 2.04(0.81-5.15) 52(54.7) 43(45.3) 1.14(0.60-2.14)
      No 36(55.4) 28(44.6) 1.00 1.00 33(50.8) 31(49.2) 1.00
Sleeping 
duration/24hr
     6-8 hour 49(57.0) 37(43.0) 1.00 1.00 41(47.8) 45(52.3) 1.00
   <6 hour 17(81.0) 4(19.0) 3.21(0.99-10.33) 1.49(0.33-6.81) 10(47.6) 11(52.4) 0.99(0.38-2.59)
  >8 hour 40(76.9) 12(23.1) 2.52(1.16-5.46)* 1.01(0.36-2.85) 34(63.4) 18(34.6) 2.07(1.02-4.22)*
Note: *Statistically significant association, 1: Reference category
NCEP-ATPIII: National Cholesterol Education Program Adult Treatment Panel III
IDF: International Diabetes Federation
BMI: Body Mass Index
FBS: Fasting Blood Sugar
AOR: Adjusted Odds Ratio
COR: Crude Odds Ratio
CI: Confidence Interval
DISCUSSION
MetS is a cluster of the most dangerous heart 
attack risk factors: diabetes and raised fasting 
plasma glucose, abdominal obesity, elevated TG, 
low HDL and high blood pressure (1, 4). The 
overall prevalence of MetS in the study was 
53.5% in IDF whereas 66.7% in the NCEP-ATPIII 
criteria. Previous studies also pointed out similar 
prevalence among T2DM population, Nigeria 
62.5% (17) and Ghana 58%(18). Conversely,
higher rate of MetS than the finding of this study 
was reported among DM patients 70-80 % (7), 
76% in Abbottabad (19) according to NCEP-
ATPIII and 66% based on IDF criteria (20). Other 
previous studies also reported higher prevalence of  
MetS in Nepalese (73.9%) and (66.8%) (21), 
Malaysia (96.1%),  (84.8%) (14) T2DM patients 
according to NCEP ATP III and IDF definitions, 
respectively. 
Lower prevalence of MetS was reported in 
T2DM patients in Bosnia and Herzegovina 
(47.91%) (22), in  Ethiopian hypertensive patients 
(40.7%) and (39.3%) (10) using NCEP-ATPII and 
IDF criteria respectively. These differences in the 
prevalence of MetS can be explained by the 
interaction of genetic and environmental factors, 
rapid urbanization and the adoption of unhealthy 
lifestyle which predispose individuals to different 
risk factors of MetS (6).
The prevalence of the MetS is strongly 
dependent on the different cut-off points and sets 
of criteria used by different definitions. In this 
study, slightly higher prevalence of MetS was 
observed by ATP III definition in comparison with 
IDF (66.7% vs.53.5 %). It could be attributed to 
the relative flexibility of the ATP III in which 
abdominal obesity is not considered as a 
prerequisite for the diagnosis and to the fact that 
criteria are more broadly focused on specific 
cardiovascular risk factors. Although it has been 
well understood that the international 
anthropometric cutoffs for detection of body 
fatness and risk of MetS are not appropriate for 
Ethiopians and some Asian countries to determine 
MetS.Ethiopians have higher body fat at a 
relatively low BMI because of the slender body 
frame compared with a Caucasians or black 
person from another country which predisposes 
them to very higher risk of MetS, T2DM and CVD 
than any other population in the world (23).
Except for this difference, the ATP III and IDF 
definitions are essentially fair as seen by the 
degree of agreement (kappa statistic= 0.472) 
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which is in agreement with the Bangladesh study
(24). 
In this study, central obesity and 
hypertriglyceridemia were most prevalent 
components of the MetS in agreement to a study 
in Ethiopia (8). This finding is not surprising 
given the observation that central obesity plays a 
key role in the development of the MetS and 
appears to precede the appearance of the other 
MetS components. However, it is pertinent to note 
that although the specific role of central obesity in 
patients with the MetS remains unexplained;
active brown adipocytes which accumulate in 
central locations have been found to be 
metabolically active. A small proportion T2DM 
have all the components of the MetS in this study. 
This is in contradistinction to the report (25) who 
reported the absence of a combination of four 
components of MetS in their study participants.
The frequency of individual MetS 
components were predominantly higher in females 
compared to males in both criteria with central 
obesity and hypertriglyceridemia predominantly
elevated. It is consistent with the report of an 
earlier study (26) but conflicting with studies in 
Nepal which identfied central obesity as the most 
prevalent  and hypertension  as the least prevalent 
components of MetS (21,27).
From multivariable analysis, participants who 
had high BMI, longer duration of illness since 
T2DM diagnosis, age, sex and having poor 
glycemic control are significantly associated with 
MetS. There were variations in the prevalence of 
each of the distinct risk factors of MetS by sex. 
For instance, previous studies supported a 
significantly elevated body weight, WC, and low 
HDL-cholesterol, hypertensive, dyslipidemia and 
poor glycemic control observed in women than 
men (10,26). The observation of sex difference in 
body fat distribution, IR, sex hormones and the 
effect of glucose, pro-inflammatory state, 
decreased growth hormone secretion, 
hypogonadism and stress induced hyper-
cortisolism could have casual effects although the 
role of these may vary depending on ethnic group
(12). Spectacular advances in evidence based 
medicine have shown that diabetic middle aged 
women are 8 times more likely to develop 
cardiovascular events than non-diabetic (28). 
According to a large population survey conducted, 
female diabetics were more obese compared to 
male diabetics (13% and 10%, respectively) (29).
In our study, patients with MetS were sharply 
increased in the age groups of ≥58 years in both 
men and women, which was quite expected and 
supported by another study (8). On the contrary,  a 
study reported that there is  a sharp decline of the 
prevalence at very high age group due to increased 
frequency of death of individuals who were most 
susceptible to obesity-related mortality such as 
CAD and cerebrovascular events (30). 
In this study, durations of illness and 
glycemic control were significantly associated 
with MetS which is supported by previous studies 
which reported that participants who had diabetes 
for over 5 years were found to have an 11.3 times 
risk of developing MetS (31). This is contrary to 
other findings (32) in which the prevalence of 
MetS decreased along with an increase in the 
duration of diabetes. Another study also found an 
association of the MetS with less duration of 
diabetes (33). This might be due to decreased BMI 
as a result of medical intervention and better 
metabolic control, increasing awareness with the 
longer duration illness in DM patients. The 
association of the MetS with poor glycemiccontrol 
could be the result of lack of awareness and
inadequate access to quality medical care. This is 
supported by a study in Ghana which reported 
that dyslipidemia and MetS were associated with 
poor glycemic control (34).
In this study, patients with longer duration of 
sleeping had a risk of developing MetS. However, 
it was not a significant predictor of the MetS in 
our multivariable logistic regression model. 
Epidemiological studies, consistently to  our 
study, showed that long sleep duration was 
associated with MetS (35). A meta-analysis of 
observational studies indicated that short and long 
sleep durations are risky behaviors for increasing 
the risk of MetS (36). On the contrary, a number 
of studies in adults demonstrated an association 
between short sleep duration and MetS (37-39). 
The limitation of this study was its cross-sectional 
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nature amongst patients which limits our causal 
inference. 
The prevalence of MetS and its components 
using NCEP-ATPIII and IDF criteria amongst 
persons with T2DM was high. Longer duration of 
DM, poor glycemic control, high BMI, increased 
age and female sex were significantly associated 
with MetS. Education on appropriate glycemic 
control and healthy life style modification should 
be provided to control and reduce diabetes-related 
morbidity and mortality.
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